Edgewise Therapeutics' experimental drug EDG-7500 achieved its primary endpoint in a Phase 2 clinical trial for hypertrophic cardiomyopathy, a heart muscle condition. The company disclosed topline results showing the drug significantly improved exercise capacity in patients compared to placebo.
The trial enrolled patients with symptomatic obstructive hypertrophic cardiomyopathy, a condition marked by thickened heart muscle that impedes blood flow. EDG-7500, a cardiac myosin inhibitor, demonstrated a statistically significant improvement in peak oxygen uptake (pVO2) at 12 weeks. Safety data appeared manageable, though specific adverse event rates were not detailed in the release.
Edgewise plans to advance EDG-7500 into a Phase 3 program following discussions with regulators. The company did not specify a timeline for filing or potential FDA submission. The drug is not yet approved in any market.
Shares of Edgewise rose in premarket trading following the announcement. However, analysts noted the competitive landscape crowded by Bristol Myers Squibb's Camzyos (mavacamten) and Cytokinetics' aficamten, both of which are approved or in advanced stages for the same indication. The data leave uncertain how EDG-7500's efficacy and safety profile compares with these established therapies, the source reported.
A key caveat: the trial results do not include head-to-head data against Camzyos or aficamten, making comparative effectiveness difficult to assess. Long-term outcomes and tolerability beyond the 12-week endpoint remain unknown, and the Phase 2 sample size was modest.